California’s Largest Life Science Association
Biocom works on behalf of over 1,300 members to drive public policy, build an enviable network of industry leaders, create access to capital, create robust value-driven purchasing programs and introduce cutting-edge workforce development and STEM education programs.
Biocom also offers 20+ targeted committees where members join fellow thought leaders to create actionable change in California’s life science community.
To view the Biocom Member Directory, login to the Biocom Member Community.
“As past Chairman and current Board member of Biocom, I am thrilled that this organization continues to have such an impactful role in building the Life Science industry in California and in doing so contributes in a big way to the innovation economy. On a personal note, I treasure the time I spend on this dedicated Board with so many passionate and innovative leaders of this great industry.”
Magda Marquet, Co-Chairman & Founder, Althea
“”Biocom is giving TÜV SÜD a valuable forum to connect with and support our most valued local customers. As a leading Notified Body offering global regulatory approvals, we plan to support Biocom’s active agenda and events schedule and to collaborate with all industries to support and drive innovation in the life science and medical device industry.””
Richard DeRisio, Vice President, Medical Health Serivces, Americas, TUV SUD America Inc.
“I have had the opportunity to give presentations to VCs and Pharma Venture Funds at several Venture Day events. These experiences have been very helpful with respect to meeting investors from outside the San Diego area and also for valuable feedback. This is an important Biocom program!”
Michael J. Newman, CEO, Decoy Biosystems
“”Presenting at Biocom this year helped put Forge on the radar of several investors seeking to put money to work in the antibiotic space. The conference not only gave me the opportunity to meet the interested investors face-to-face but also gave me a platform to describe our funding strategy and growth trajectory, which gave us additional momentum leading to upsizing our Series A round. In fact, after my presentation multiple investors that were ‘circling the hoop’ were now ready to jump into the game and asked if they could participate in the Series A financing.””
Zachary Zimmerman, Ph.D, CEO, Forge Therapeutics, Inc.
“The Biocom team has helped LJI by having every level of government personally visit LJI and we’re able to show them all the great work we are doing.”
Albin Soares, Director, Research Relations and Executive Director, La Jolla Institute for Allergy & Immunology